To establish the ten-color flow cytometry for measuring T cell subpopulations and their activated state in the peripheral blood of HIV/AIDS patients.

The monoclonal antibodies targeting cell surface antigen CD3, CD4, CD8, CD45RA, CD25, CCR7, CD28, CD38 and HLA-DR to establish the ten-color panel were used. One peripheral blood PBMC sample from a HIV/AIDS patient was applied for adjustment of voltage, compensation and FMO control. After that peripheral blood samples, of 5 patients with HIV/AIDS were analyzed by ten-color flow cytometry.

The ten-color flow cytometric staining method was established for the measurement of T cell subpopulations and activation state in human peripheral blood. This method was applied to detect peripheral blood samples from 5 patients with HIV/AIDS and was able to evaluate the immune status of these patients. And then the percentage of T lymphocyte subgroup and the activation level were detected, respectively. The expression patterns of HLA-DR, CD38 and CD28 in different subpopulations were with significant difference.

The ten-color flow cytometry was a simple and reliable method for the analysis of T cell subpopulations and their activation in HIV/AIDS patients.

To investigate the differences between the levels of apolipoprotein B mRNA editing enzyme catalytic polypeptide 3G (APOBEC3G) in different stages of HBV infection and during the different periods treated with different antiviral drugs, and to speculate on the role of innate immunity in antiviral therapy.

Total of 30 cases of chronic hepatitis B (CHB) who were treated with polyethylene glycol interferon alpha-2a and 30 patients treated with entecavir were selected, 20 patients with CHB and 20 patients with hepatitis B cirrhosis were selected; while 20 healthy adults collected as controls. The HBV DNA load and ALT levels were detected, and the level of APOBEC3G mRNA in peripheral blood mononuclear cells (PBMCs) was analyzed by fluorescence quantitative PCR.

Compared with healthy cases, during the period of using entecavir and interferon of patients with CHB and liver cirrhosis and antiviral. The levels of APOBEC3G mRNA in patients’ PBMCs were increased by 1.4 times (t =-3.166, P = 0.003), 1.37 times (t =-2.206, P = 0.0335), 1.44 times (t =-3.381, P = 0.0014) and 3.95 times (t = -4.790, P = 0.0002) . There was no significant difference in the levels of APOBEC3G mRNA between the patients treated with entecavir and the patients without any treatment (t =-0.242, P = 0.8097). The levels of APOBEC3G mRNA in patients treated with interferon was 2.36 times (t = 4.085, P = 0.0002), 2.40 times (t = 4.9, P < 0.0001) as that in patients without any treatment and patients treated with entecavir, respectively. The levels of APOBEC3G mRNA in patients with high levels of ALT was 1.35 times higher than that of patients with normal level of ALT (t = 2.667, P = 0.0112). The levels of HBV DNA was not related to the content of APOBEC3G mRNA (F = 0.2124, P = 0.8871).

APOBEC3G plays an important role in the antiviral therapy of interferon.

To investigate the value of clinical pulmonary infection score (CPIS) and procalcitonin (PCT) in the treatment of elderly patients with severe community-acquired pneumonia (SCAP).

Total of 60 elderly patients with SCAP in our hospital from February 2014 to February 2016 were collected. According to the prognosis, the patients were divided into survival group and death group. The difference of PCT, white blood cell (WBC), CPIS score between the two groups at the first day and 7th day after hospital admission were detected and their correlations with CPIS were analyzed.

Compared with the first day, the levels of PCT and CPIS in the survival group were not significantly decreased at the 7th day after hospital admission (P all < 0.001), but the WBC was without significant change (P > 0.05). Compared with the first day, the levels of WBC, PCT and CPIS in the death group were not significantly changed (P all > 0.05). After 7 days treatment, there were significant difference in PCT and CPIS between the two groups (P all < 0.05). WBC, PCT, and CPIS in SCAP patients had no significant correlation with prognosis on the first day (P all > 0.05). After 7 days treatment, WBC was not associated with prognosis (P > 0.05), and PCT and CPIS were significantly correlated with the prognosis of SCAP (r = 0.44, P = 0.023; r = 0.58, P = 0.017).

PCT and CPIS were associated with severity and prognosis in elderly patients with SCAP in elderly patients. It could be used as a good biomarker for evaluating the prognosis of SCAP, which could be used for further treatment.